Recently, PZP has been reported to act as a potential biomarker for screening the risk of lung adenocarcinoma (Yang et al., 2021) or prognosis of hepatocellular carcinoma (Zhang et al., 2019) in patients with type 2 diabetes. This evidence concerns the gene PZP and lung adenocarcinoma.